Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed exchanges that its subsidiary Optival Health Solutions Private Limited received a 4-day suspension order on a drug license for one retail store located at Modi Splendour, Quthubullapur, Telangana. The order was issued by the Assistant Director, Drugs Control Administration, Quthubullapur, and was received on 14.08.2025, citing a violation under Rule 65 of the Drugs and Cosmetics Act, 1940 and the associated Rules of 1945. The company has disclosed the potential revenue loss at approximately Rs 0.80 lacs (around Rs 80,000) due to the suspension. The disclosure is being made under SEBI Listing Regulations read with the relevant SEBI circulars on material event reporting.
The impact is negligible — a single store suspended for 4 days with only about Rs 0.80 lakh of potential revenue loss, which is insignificant for a large pharmacy retail chain like Medplus. No material effect on operations, financials, or shareholder value is expected.